- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc stock price live, this page displays NASDAQ ARQT stock exchange data. View the ARQT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Arcutis Biotherapeutics Inc real time stock price chart below.
What Is the Arcutis Biotherapeutics Inc Stock Price Today?
The Arcutis Biotherapeutics Inc stock price today is 14.85.
What Is the Stock Symbol for Arcutis Biotherapeutics Inc?
The stock symbol for Arcutis Biotherapeutics Inc is ""ARQT.""
What Stock Exchange Does Arcutis Biotherapeutics Inc Trade On?
Arcutis Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Arcutis Biotherapeutics Inc a Good Stock to Buy?
Determining whether Arcutis Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARQT quote. (ISIN: US03969K1088)
What Is the Arcutis Biotherapeutics Inc Stock Price Today?
The Arcutis Biotherapeutics Inc stock price today is 14.85.
What Is the Stock Symbol for Arcutis Biotherapeutics Inc?
The stock symbol for Arcutis Biotherapeutics Inc is ""ARQT.""
What Stock Exchange Does Arcutis Biotherapeutics Inc Trade On?
Arcutis Biotherapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Arcutis Biotherapeutics Inc a Good Stock to Buy?
Determining whether Arcutis Biotherapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARQT quote. (ISIN: US03969K1088)
NASDAQ
Currency in USD
14.85
+0.30(+2.06%)
Real-time Data·
Fair Value
An estimate of a Arcutis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.44
14.99
52 wk Range
7.86
17.75
ARQT Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
ARQT is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Arcutis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.4414.99
52 wk Range
7.8617.75
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARQT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Arcutis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
21.71
Upside
+46.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Arcutis Biotherapeutics Inc Company Profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics Inc Earnings Call Summary for Q1/2025
- Q1 2025 EPS beat at -$0.20 vs -$0.21 forecast; revenue of $65.8M exceeded $63.66M estimate; 196% YoY growth
- Stock fell 6.96% in regular trading, 6.22% after hours despite beat; gross profit margin at 90.27%
- Anticipating approvals for Xerive foam (psoriasis) and cream (atopic dermatitis) in 2025
- Cash flow breakeven expected by 2026; cash and marketable securities at $198.7M
- Management confident in prescription growth; patent litigation with Petagus on indefinite stay
Last Updated: 06/05/2025, 22:44
Read Full TranscriptCompare ARQT to Peers and Sector
Metrics to compare | ARQT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARQTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −13.5x | −4.7x | −0.5x | |
PEG Ratio | −0.22 | 0.02 | 0.00 | |
Price/Book | 12.3x | 8.9x | 2.6x | |
Price / LTM Sales | 8.2x | 8.9x | 3.2x | |
Upside (Analyst Target) | 37.5% | 121.3% | 42.7% | |
Fair Value Upside | Unlock | 8.6% | 5.8% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 21.71
(+46.22% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-0.20 / -0.21
Revenue / Forecast
65.80M / 63.66M
People Also Watch
FAQ
What Stock Exchange Does Arcutis Trade On?
Arcutis is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Arcutis?
The stock symbol for Arcutis is "ARQT."
What Is the Arcutis Market Cap?
As of today, Arcutis market cap is 1.78B.
What Is Arcutis's Earnings Per Share (TTM)?
The Arcutis EPS (TTM) is -1.04.
When Is the Next Arcutis Earnings Date?
Arcutis will release its next earnings report on 12 Aug 2025.
From a Technical Analysis Perspective, Is ARQT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Arcutis Stock Split?
Arcutis has split 0 times.
How Many Employees Does Arcutis Have?
Arcutis has 342 employees.
What is the current trading status of Arcutis (ARQT)?
As of 23 Jul 2025, Arcutis (ARQT) is trading at a price of 14.85, with a previous close of 14.55. The stock has fluctuated within a day range of 14.44 to 14.99, while its 52-week range spans from 7.86 to 17.75.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.